FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHA Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor [NCT06065540]RESEARCHSemaglutide in Alcohol Use Disorder [NCT07949474]RESEARCHEffects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease [NCT06409130]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]NEWS‘Selling and marketing snake oil’: The debate over compounded GLP-1sRESEARCHSemaglutide Effects on Sperm Concentration in Overweight Infertile Men [NCT07946796]RESEARCHTirzepatide for the REduction of AceTazolamide in Idiopathic Intracranial Hypertension [NCT07946315]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHA Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor [NCT06065540]RESEARCHSemaglutide in Alcohol Use Disorder [NCT07949474]RESEARCHEffects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease [NCT06409130]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]NEWS‘Selling and marketing snake oil’: The debate over compounded GLP-1sRESEARCHSemaglutide Effects on Sperm Concentration in Overweight Infertile Men [NCT07946796]RESEARCHTirzepatide for the REduction of AceTazolamide in Idiopathic Intracranial Hypertension [NCT07946315]

Solo a fini di ricerca. Disposizione completa →

Ricerca/Highlighting the comparative efficacy of caloric restriction versus liraglutide treatment in managing obesity and prediabetes, emphasizing the importance of personalized intervention strategies.
Torna alla Biblioteca di Ricerca
glucagon-like peptide-1 receptor agonistliraglutide

Highlighting the comparative efficacy of caloric restriction versus liraglutide treatment in managing obesity and prediabetes, emphasizing the importance of personalized intervention strategies.

May 17, 2026
Share

Paper di Sorgente

Effect of the glucagon-like peptide-1 receptor agonist liraglutide, compared to caloric restriction, on appetite, dietary intake, body fat distribution and cardiometabolic biomarkers: A randomized trial in adults with obesity and prediabetes.

Silver Heidi J et al.Diabetes, obesity & metabolism2023
Ricerche Emergenti

Fondato su ricerche emergenti. Questi risultati sono promettenti ma richiedono ulteriori verifiche.

Informazioni sull'Analisi

Questo articolo spiega i risultati del paper di sorgente sopra menzionato in linguaggio accessibile per la comunità della ricerca peptide. Il nostro obiettivo è evidenziare ciò che conta di più — le implicazioni pratiche, la forza delle prove e cosa significa per la ricerca in corso.

Caloric Restriction Outperforms Liraglutide in Weight Loss and Body Composition Improvement for Prediabetes Patients

Published: May 17, 2026 | Source: Diabetes, obesity & metabolism (2023) | Category: glucagon-like peptide-1 receptor agonist, liraglutide

Overview

A recent study published in Diabetes, Obesity & Metabolism compared the effects of caloric restriction and the glucagon-like peptide-1 receptor agonist (GLP-1RA) liraglutide on weight loss and body composition improvement among adults with obesity and prediabetes. The findings suggest that while both methods are beneficial for cardiometabolic risk reduction, caloric restriction leads to greater weight loss and more favorable changes in body fat distribution.

Study Background

Previous research has highlighted the benefits of GLP-1RAs like liraglutide in managing type 2 diabetes and obesity. However, questions remain about their comparative efficacy against traditional dietary interventions such as caloric restriction. This study aimed to address these gaps by comparing weight loss outcomes between caloric restriction and liraglutide treatment.

What the Research Found

The randomized trial involved 88 adults with obesity and prediabetes who were assigned to one of three groups: caloric restriction (-390 kcal/day), liraglutide (1.8 mg/day), or sitagliptin (a DPP-4 inhibitor used as a control). After 14 weeks, the study found that:

  • Weight Loss: Caloric restriction led to weight loss in 44% of participants, compared to 22% for liraglutide and only 5% for sitagliptin.
  • Body Composition: The ratio of fat to lean mass decreased by 6.5% with caloric restriction versus 2.2% with liraglutide, while there was no change in the sitagliptin group.
  • Visceral Fat Reduction: Caloric restriction resulted in a 9.5% reduction in visceral fat compared to 4.8% for liraglutide and none for sitagliptin.

Additionally, spontaneous dietary changes in the caloric restriction group led to improved insulin resistance scores (HOMA-IR).

What This Means for Peptide Users

For individuals with obesity and prediabetes, this study highlights that while GLP-1RAs like liraglutide offer significant benefits, caloric restriction may be more effective in promoting weight loss and improving body composition. However, the choice of intervention should consider individual preferences and risk factors.

Limitations and Caveats

The study's small sample size (88 participants) limits its generalizability to broader populations. Additionally, the short duration (14 weeks) means long-term effects remain uncertain. These limitations underscore the need for further research to confirm these findings in larger and more diverse groups over extended periods.

How This Compares to Previous Research

While previous studies have shown positive outcomes with GLP-1RAs like liraglutide, this study provides a direct comparison against caloric restriction. Other research has also indicated the benefits of dietary interventions for improving metabolic health, aligning with these findings but emphasizing the need for personalized approaches.

Our Analysis

PeptideVault views this study as valuable in providing evidence-based insights into weight management strategies for prediabetes patients. The comparative analysis offers a nuanced understanding of how different treatments can impact body composition and cardiometabolic risk factors differently. However, the limitations noted highlight the importance of cautious interpretation until further validation is achieved.

Key Takeaways

  • Caloric Restriction Outperforms: Caloric restriction leads to greater weight loss and more favorable changes in body fat distribution compared to liraglutide.
  • Personalized Interventions: The study supports a personalized approach to treatment, considering individual preferences and risk factors for optimal outcomes.
  • Further Research Needed: Larger studies over longer durations are required to confirm these findings and explore long-term effects.

Original Source

Citation: Silver Heidi J, Olson Dianna, Mayfield Dustin et al. (2023). Effect of the glucagon-like peptide-1 receptor agonist liraglutide, compared to caloric restriction, on appetite, dietary intake, body fat distribution and cardiometabolic biomarkers: A randomized trial in adults with obesity and prediabetes.. Diabetes, obesity & metabolism. DOI: 10.1111/dom.15113

Access:

---

This article is for informational and research purposes only. PeptideVault summarizes and analyzes published research. Always consult a licensed healthcare provider.

Nota dell'Editor

Questa analisi è stata preparata dal team di ricerca di Peptide Contacts. Invitiamo i lettori a verificare le informazioni con il paper originale completo per metodologia e dati completi. L'originale pubblicazione è disponibile su PubMed.

Ricerche correlate

Comments

Sign in to join the discussion

Questa analisi è stata generata da ricerche peer-reviewed per scopi educativi solo. Non costituisce consiglio medico. Consulta sempre un professionista sanitario qualificato prima di utilizzare qualsiasi terapia basata su peptide.